Recent advances in immunotherapy for allergic diseases

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 8, Issue 1, 2014, Pages 24-35

  El Qutob, David ^a   Mencia, Gemma ^a   Fernandez Caldas, Enrique ^a  

^a HOSPITAL DE LA PLANA   (Spain)

Author keywords

Allergoid; Allergy; Asthma; House dust mite; Immunotherapy; Parvalbumin; Rhinitis

Indexed keywords

ALLERGEN; BET V 1; CARBON NANOTUBE; OVALBUMIN; PARVALBUMIN; PEPTIDE; POLLEN ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGENICITY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; HOUSE DUST ALLERGY; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; NONHUMAN; PARIETARIA; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PICHIA PASTORIS; POLLEN ALLERGY; PRIORITY JOURNAL; RAGWEED POLLEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VACCINATION;

ALLERGENS; AMBROSIA; ANIMALS; ANTIGENS, PLANT; BETULA; CATS; DESENSITIZATION, IMMUNOLOGIC; HORSES; HUMANS; HYPERSENSITIVITY; PARIETARIA; POLLEN; PYROGLYPHIDAE;

EID: 84895448815     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872213X07666131113111159     Document Type: Review

References (106)

1. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001; 22(4): 185-9.
2. Bousquet J., Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160.
3. Becker EC, Wolke G, Heinrich J. Bronchial responsiveness, spirometry and mortality in a cohort of adults. J Asthma 2013; 50(4): 427-32.
4. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 1994; 94(2 Pt 1): 182-8.
5. Barranco P, Galan I, Cid A, Vall A. Epidemiologia y etiopatogenia del asma, in Tratado de Alergologia, Pelaez A, Davila I, Eds. Ergon: Madrid 2007.
6. Loureiro G, Rabaca MA, Blanco B, Andrade S, Chieira C, Pereira C. Aeroallergens sensitization in an allergic paediatric population of Cova da Beira, Portugal. Allergol Immunopathol (Madr) 2005; 33(4): 192-8.
7. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24(5): 758-64.
8. Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: From mechanisms to meta-analyses. Chest 2012; 141(5): 1303-14.
9. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010(8): CD001186.
10. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11(6): 586-93.
11. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-Year follow-up on the PAT study. Allergy 2007; 62(8): 943-8.
12. Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007; 35(2): 44-51.
13. Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol 2012; 109(5): 348-352 e2.
14. Virkud YV, Vicker, BP. Advances in immunotherapy for food allergy. Discov Med 2012;14(76): 159-65.
15. Beyer K. A European perspective on immunotherapy for food allergies. J Allergy Clin Immunol 2012; 129(5): 1179-84.
16. Land MH, Burks AW. Future of immunotherapy for food allergy. Immunotherapy 2012; 4(1): 13-5.
17. Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy: Therapeutic vaccines for allergic diseases A WHO position paper. J Allergy Clin Immunol 1998; 102(4): 558-62.
18. Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, et al. Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement. Pediatr Allergy Immunol 2012; 23(4): 300-6.
19. Soyka MB, Holzmann D, Akdis CA. Regulatory cells in allergenspecific immunotherapy. Immunotherapy 2012; 4(4): 389-96.
20. Maggi E, Vultaggio A, Matucci A. T-cell responses during allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2012; 12(1): 1-6.
21. Jacobsen L, Wahn U, Bilo MB. Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: The effects of immunotherapy can be categorised by level of benefit-the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy 2012; 2: 8.
22. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2(6): 446-53.
23. Birkner T, Rumpold H, Jarolim E, Ebner H, Breitenbach M, Skvaril F, S et al. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Allergy 1990; 45(6): 418-26.
24. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67(2): 217-26.
25. Wachholz PA, Kristensen SN, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112(5): 915-22.
26. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010; 40(5): 1232-40.
27. Jutel M, Akdis CA. Immunological mechanisms of allergenspecific immunotherapy. Allergy 2011; 66(6): 725-32.
28. Anderson AE, Mackerness KJ, Aizen M, Carr VA, Nguyen D, Du Pre F, et al. Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population. Clin Exp Allergy 2009; 39(11): 1693-9.
29. Warrington R. Immunotherapy in asthma. Immunotherapy 2010; 2(5): 711-25.
30. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 2012; 67(3): 302-11.
31. von Moos S, Kundig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: A review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011; 31(2): 391-406.
32. Pauli G, Malling HJ. The current state of recombinant allergens for immunotherapy. Curr Opin Allergy Clin Immunol 2010; 10(6): 575-81.
33. Platts-Mills TA., Chapman MD. Dust mites: Immunology, allergic disease, and environmental control. J Allergy Clin Immunol 1987; 80(6): 755-75.
34. Tanyaratsrisakul S, Malainual N, Jirapongsananuruk O, Smith WA, Thomas WR, Piboonpocanun S. Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastoris. Int Arch Allergy Immunol 2010; 151(3): 190-8.
35. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002; 129(1): 1-18.
36. Chen KW, Fuchs G, Sonneck K, Gieras A, Swoboda I, Douladiris N, et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol 2008; 45(9): 2486-98.
37. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997; 15(8): 754-8.
38. Walgraffe D, Matteotti C, El Bakkoury M, Garcia L, Marchand C, Bullens D, et al. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol 2009; 123(5): 1150-6.
39. Asturias JA, Ibarrola I, Arilla MC, Vidal C, Ferrer A, Gamboa PM, et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy 2009. 39(7): 1088-98.
40. Bussieres L, Bordas-Le Floch V, Bulder I, Chabre H, Nony E, Lautrette A, et al. Recombinant fusion proteins assembling Der p 1 and Der p 2 allergens from Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2010; 153(2): 141-51.
41. Chen KW, Vrtala S, Valenta R. Hypoallergenic polypeptides for the treatment of house dust mite allergy. EP2460824 (2012).
42. Bordas, V., Bussieres, L., Airouche, S., Tourdot, S., Nony, E., Moingeon, P., Bouley, J. Recombinant Der P 2 expressed in Pichia pastoris as a "Natural-Like" allergen for immunotherapy and diagnostic purposes. US20110293665 (2011).
43. Breiteneder, H., Radauer, C. A classification of plant food allergens. J Allergy Clin Immunol 2004; 113(5): 821-30; quiz 831.
44. Son DY, Scheurer S, Hoffmann A, Haustein D, Vieths S. Pollenrelated food allergy: Cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen. Eur J Nutr 1999; 38(4): 201-15.
45. Jahn-Schmid B, Radakovics A, Luttkopf D, Scheurer S, Vieths S, Ebner C, et al. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 2005; 116(1): 213-9.
46. Wagner S, Radauer C, Bublin M, Hoffmann-Sommergruber K, Kopp T, Greisenegger EK, et al. Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J Allergy Clin Immunol 2008; 121(1): 246-52.
47. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122(5): 951-60.
48. Bauer R, Scheiblhofer S, Kern K, Gruber C, Stepanoska T, Thalhamer T, et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: Preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 2006; 118(1): 269-76.
49. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14677-82.
50. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38(9): 1514-25.
51. Pree I, Shamji MH, Kimber I, Valenta R, Durham SR, Niederberger V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010; 40(9): 1346-52.
52. Reymond, C., Spertini, F. Contiguous overlapping peptides for treatment of birch pollen allergy. US20100203070 (2010).
53. Gonzalez-Rioja R, Ibarrola I, Arilla MC, Ferrer A, Mir A, Andreu C, et al. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 120(3): 602-9.
54. Sturaro, M., Viotti, A., Genga, A., Falagiani, P., Mistrello, G., Roncarolo, D., Zanotta, S. Variants of the major allergen Par j 2 of Parietaria judaica. WO2002022674 (2002).
55. Bonura A, Corinti S, Artale A, Di Felice G, Amoroso S, Melis M, et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int Arch Allergy Immunol 2007; 142(4): 274-84.
56. Mistrello, G., Zanotta, S., Roncarolo, D., Falagiani, P. Hybrid proteins from Parietaria judaica major allergens and uses thereof. EP2281836 (2012).
57. Hernandez J. Salud rural. Ed. XVII. Universidad de Madrid. Madrid. 2000.
58. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11(4): 446-9.
59. Hulse KE, Reefer AJ, Engelhard VH, Satinover SM, Patrie JT, Chapman MD, et al. Targeting Fel d 1 to FcgammaRI induces a novel variation of the T(H)2 response in subjects with cat allergy. J Allergy Clin Immunol 2008; 121(3): 756-762 e4.
60. Gronlund H, Saarne T, Gafvelin G, van Hage M. The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol 2010; 151(4): 265-74.
61. Nilsson OB, Adedoyin J, Rhyner C, Neimert-Andersson T, Grundstrom J, Berndt KD, et al. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One 2011; 6(9): e24558.
62. Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127(6): 1562-70 e6.
63. Grundstrom J, Neimert-Andersson T, Kemi C, Nilsson OB, Saarne T, Andersson M, et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol 2012; 157(2): 136-46.
64. Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012. 129(5): 1290-6.
65. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150(1): 59-65.
66. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127(1): 89-97.
67. Saarne T, Kaiser L, Gronlund H, Rasool O, Gafvelin G, van Hage-Hamsten, M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy 2005; 35(5): 657-63.
68. Hafner, R., Larche, M., Kay, A. Vaccine peptide combinations against cat allergy. EP2428222A2 (2012).
69. Roost HP, Kunzli N, Schindler C, Jarvis D, Chinn S, Perruchoud AP, et al. Role of current and childhood exposure to cat and atopic sensitization. European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104(5): 941-7.
70. Plaschke P, Janson C, Norrman E, Bjornsson E, Lundback B, Lindholm N, et al. Skin prick tests and specific IgE in adults from three different areas of Sweden. Allergy 1996; 51(7): 461-72.
71. King TP, Norman PS, Lichtenstein LM. Isolation and characterization of allergens from ragweed pollen. IV. Biochemistry 1967; 6(7): 1992-2000.
72. Rafnar T, Griffith IJ, Kuo MC, Bond JF, Rogers BL, Klapper DG. Cloning of Amb a I (antigen E), the major allergen family of short ragweed pollen. J Biol Chem 1991; 266(2): 1229-36.
73. Jahn-Schmid B, Wopfner N, Hubinger G, Asero R, Ebner C, Ferreira F, et al. The T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements. J Allergy Clin Immunol 2010; 126(5): 1068-1071. e2.
74. Asai K, Foley SC, Sumi Y, Yamauchi Y, Takeda N, Desrosiers M, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis. Allergol Int 2008; 57(4): 377-81.
75. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113(6): 1144-51.
76. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106(1 Pt 1): 124-34.
77. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-55.
78. Larche, M., Hafner, R., Laidler, P. Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy. EP2433639 (2012).
79. Andersson K, Lidholm, J. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003; 130(2): 87-107.
80. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold--high cost to society. Allergy 2010; 65(6): 776-83.
81. Ohlin, P., Lindstedt, M., Levin, K. Novel therapies. WO2013104901 (2013).
82. Wüstenberg, E. Use of an adjuvanted allergy vaccine formulation for parenteral administration. EP1974746 (2012).
83. Campana, R., Valenta, R., Vrtala, S., Swoboda, I., Gieras, A., Spitzauer, S., Valent, P., Blatt, K., Focke-tejkl, M., Linhart, B., Kraft, D. Hypallergenic mosaic antigens and methods of making same. US20120009210 (2012).
84. Jacobi, H., Lundegaard, A., Houghton, C., Aasmul-olsen, S., Mærkedahl, L., Andersen, J. An allergen dosage form. EP2436395 (2012).
85. Ventura MT, Giuliano G, Buquicchio R, Accettura F, Carbonara M. Local and systemic reactions occurring during immunotherapy: An epidemiological evaluation and a prospective safety-monitoring study. Immunopharmacol Immunotoxicol 2008; 30(1): 153-61.
86. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63(3): 374.
87. Mistrello, G., Roncarolo, D., Zanoni, D., Zanotta, S., Falagiani, P. Allergoids derived from allergenes. EP2320946 (2012).
88. Romagnani, S., Maggi, E., Parronchi, P., Guarna, A., Occhiato, E. Preparation of conjugates comprising adenine derivatives and allergenic proteins and their use for specific immunotherapy of allergenic diseases. WO2012017408 (2012).
89. Dahlman-Hoglund A, Dahlgren U, Ahlstedt S, Hanson LA, Telemo E. Bystander suppression of the immune response to human serum albumin in rats fed ovalbumin. Immunology 1995; 86(1): 128-33.
90. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991; 174(4): 791-8.
91. Wang LF, Chen JS, Hsu CJ, Liu CY, Yu JS, Miaw SC. Antigendriven bystander effect accelerates epicutaneous sensitization with a new protein allergen. J Biomed Sci 2009; 16: 28.
92. Brimnes, J., Lund, K. Supression of a hypersensitivity immune response with unrelated antigen derived from allergen source material. WO2012049310 (2012).
93. Spertini, F., Corthesy, B. Allergen peptide fragments and use thereof for treatment of dust mite allergies. US20120100167 (2012).
94. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: A review. Crit Rev Ther Drug Carrier Syst 2002;19(2): 99-134.
95. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75(1): 1-18.
96. Kalkanidis M, Pietersz GA, Xiang SD, Mottram PL, Crimeen-Irwin B, Ardipradja K, et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 2006; 40(1): 20-9.
97. Bramwell VW, Perrie Y. Particulate delivery systems for vaccines: What can we expect? J Pharm Pharmacol 2006; 58(6): 717-28.
98. De Souza J, Esparza I, Ferrer M, Sanz M, Irache J, Gamazo C. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol 2012; 2012: 474605.
99. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: Experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004;4(6): 543-8.
100. Wheeler, A.W. and Woroniecki, S.R., Immunological adjuvants in allergy vaccines: Past, present and future. Allergol Int 2001; 50(4): 295-301.
101. Fahmy, T., Pfefferle, L., Haller, G. Carbon nanotube compositions and methods of use thereof. US20130216581 (2013).
102. Von Andrian, U., Farokhzad, O., Langer, R., Junt, T., Moseman, E., Basto, P., Iannacone, M., Alexis, F., Zhang, L. Vaccine nanotechnology. US20130236533 (2013).
103. Rask C, Lund L, Lund G, Heydenreich B, Wurtzen P, Bellinghausen I, et al. An alternative allergen: Adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy. Clin Exp Allergy 2012; 42(9): 1356-68.
104. Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 2012; 67(5): 630-7.
105. Dominicus R. 3-Years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Eur Ann Allergy Clin Immunol 2012; 44(3): 135-40.
106. Deifl S, Bohle B. Factors influencing the allergenicity and adjuvanticity of allergens. Immunotherapy 2011; 3(7): 881-93.